Biomarkers for Cancer Screening, Diagnosis and Targeted Therapeutic Approaches
- 1st Edition, Volume 170 - June 1, 2026
- Latest edition
- Editors: Umesh Kumar, Paul B. Fisher, Vishal Das, Kenneth D. Tew
- Language: English
Biomarkers for Cancer Screening, Diagnosis and Targeted Therapeutic Approaches, Volume 170 provides an integrated overview of the current state and future directions of biomar… Read more
Biomarkers for Cancer Screening, Diagnosis and Targeted Therapeutic Approaches, Volume 170 provides an integrated overview of the current state and future directions of biomarker research in oncology. The book bridges fundamental molecular insights with clinical applications, emphasizing how biomarkers are transforming cancer detection, diagnosis, prognosis, and personalized treatment strategies. Chapters cover an Introduction to cancer biomarkers and current research, Role of Biomarkers for cancer detection, diagnosis, and treatment, Classification of Cancer Biomarkers based on treatment strategies, Predictive, Prognosis and Diagnostic Cancer Biomarker in cancer therapeutic approaches, Biomarkers for targeted therapy and treatment decision-making, and much more.
Additional sections delve in to Emerging trends in cancer biomarker and their clinical effect on personalized treatment, Recent advances in detection techniques regarding predictive, prognostic and diagnostic biomarkers in solid cancers and its future challenges, Recent advances in detection techniques regarding predictive, prognostic and diagnostic biomarkers in body fluids and its future challenges, Emerging biomarkers for non-invasive cancer diagnosis and treatment, and more. The brings together recent advancements in molecular diagnostics, predictive and prognostic markers, and targeted therapeutic development across a wide range of cancer types.
Additional sections delve in to Emerging trends in cancer biomarker and their clinical effect on personalized treatment, Recent advances in detection techniques regarding predictive, prognostic and diagnostic biomarkers in solid cancers and its future challenges, Recent advances in detection techniques regarding predictive, prognostic and diagnostic biomarkers in body fluids and its future challenges, Emerging biomarkers for non-invasive cancer diagnosis and treatment, and more. The brings together recent advancements in molecular diagnostics, predictive and prognostic markers, and targeted therapeutic development across a wide range of cancer types.
- Bridges fundamental research on cancer biomarkers and their clinical applications
- Provides a unified understanding on how molecular mechanisms translate into diagnostic and therapeutic outcomes
- Focuses on precision and targeted oncology, highlighting emerging predictive, prognostic, and diagnostic biomarkers that support personalized treatment strategies and guide therapeutic decision-making for improved patient outcomes
- Emphasizes emerging technologies and future directions, showcasing recent advancements in biomarker detection techniques, non-invasive diagnostic tools, and future perspectives that address current limitations and inspire innovative research in cancer biomarker discovery
Oncologists, biomedical scientists, cancer researchers, molecular biologists, and healthcare professionals involved in cancer diagnostics, prognostics, and targeted therapy. It will also serve as a valuable resource for graduate and postgraduate students, academicians, and professionals in the fields of biotechnology, pharmacology, and translational medicine who seek to understand the role of biomarkers in precision oncology and personalized treatment strategies. Additionally, industry researchers and pharmaceutical professionals exploring biomarker-based drug development and clinical applications will find this book highly relevant
1. Introduction to cancer biomarkers and current research
Deeksha Pal
2. Role of Biomarkers for cancer detection, diagnosis, and treatment
Puja Sohal
3. Classification of Cancer Biomarkers based on treatment strategies
Pramodkumar P. Gupta
4. Predictive, Prognosis and Diagnostic Cancer Biomarker in cancer therapeutic approaches
Prosenjit Mridha
5. Biomarkers for targeted therapy and treatment decision-making
Manoj Kumar Jana
6. Emerging trends in cancer biomarker and their clinical effect on personalized treatment
Oluwafemi Adeleke Ojo, Olorunfemi Raphael Molehin, Clinton Ayodeji Akanbi, Adebola Busola Ojo, Julius Oluwafemi OPATOYINBO and Akingbolabo Daniel Ogunlakin
7. Recent advances in detection techniques regarding predictive, prognostic and diagnostic biomarkers in solid cancers and its future challenges
Manoj Kumar Jana, Piyal Mukherjee, Suryaprakash Tripathy, Vishnu Swarup, Umesh Kumar, Sudip Das, Anmol Gaur, Manaswini Jagadeb and Neeraj Mohan Gupta
8. Recent advances in detection techniques regarding predictive, prognostic and diagnostic biomarkers in body fluids and its future challenges
Satish Kumar Pandey, Sanjeev Kumar, Lal Chuangsangi and Girish Chandra Mohanta
9. Emerging biomarkers for non-invasive cancer diagnosis and treatment
Ashish Kumar Vyas
10. Biomarkers for Cancer Staging, Prognosis and individualised treatment
Gaurav Das, Subhabrata Guha and Jenifer Bhattacharya
11. Analysis of cancer biomarkers through estimations of molecular techniques
Manish Shukla, Meenakshi Shukla and Jai Chand Patel
12. Cancer biomarkers that are currently used in cancer therapy and under evaluations in clinical trials
Bimal Prasad Jit
13. Future perspectives and challenges for identification and recognition of clinically significant cancer biomarkers
Shiv Charan
Deeksha Pal
2. Role of Biomarkers for cancer detection, diagnosis, and treatment
Puja Sohal
3. Classification of Cancer Biomarkers based on treatment strategies
Pramodkumar P. Gupta
4. Predictive, Prognosis and Diagnostic Cancer Biomarker in cancer therapeutic approaches
Prosenjit Mridha
5. Biomarkers for targeted therapy and treatment decision-making
Manoj Kumar Jana
6. Emerging trends in cancer biomarker and their clinical effect on personalized treatment
Oluwafemi Adeleke Ojo, Olorunfemi Raphael Molehin, Clinton Ayodeji Akanbi, Adebola Busola Ojo, Julius Oluwafemi OPATOYINBO and Akingbolabo Daniel Ogunlakin
7. Recent advances in detection techniques regarding predictive, prognostic and diagnostic biomarkers in solid cancers and its future challenges
Manoj Kumar Jana, Piyal Mukherjee, Suryaprakash Tripathy, Vishnu Swarup, Umesh Kumar, Sudip Das, Anmol Gaur, Manaswini Jagadeb and Neeraj Mohan Gupta
8. Recent advances in detection techniques regarding predictive, prognostic and diagnostic biomarkers in body fluids and its future challenges
Satish Kumar Pandey, Sanjeev Kumar, Lal Chuangsangi and Girish Chandra Mohanta
9. Emerging biomarkers for non-invasive cancer diagnosis and treatment
Ashish Kumar Vyas
10. Biomarkers for Cancer Staging, Prognosis and individualised treatment
Gaurav Das, Subhabrata Guha and Jenifer Bhattacharya
11. Analysis of cancer biomarkers through estimations of molecular techniques
Manish Shukla, Meenakshi Shukla and Jai Chand Patel
12. Cancer biomarkers that are currently used in cancer therapy and under evaluations in clinical trials
Bimal Prasad Jit
13. Future perspectives and challenges for identification and recognition of clinically significant cancer biomarkers
Shiv Charan
- Edition: 1
- Latest edition
- Volume: 170
- Published: June 1, 2026
- Language: English
UK
Umesh Kumar
Dr. Umesh Kumar is a Professor in the Department of Biosciences at IMS Ghaziabad (University Courses Campus) and has led the Research Department since 2019. Previously, he served as a Scientific Officer in the Department of Biochemistry at the University of Delhi. He earned his Ph.D. in Biomedical Sciences, focusing on "Epigenetic Regulation in Breast Carcinogenesis," from the Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi, in 2013. Dr. Kumar's research interests include molecular diagnosis of cervical cancer, molecular epigenetics of breast carcinogenesis, CAR T-cell therapy, and tumor virology. He has published 50 research articles and contributed over 21 book chapters to reputable publishers. He has received multiple grants and has been honored with two Young Scientist Awards and one Senior Scientist Award. Additionally, he reviews for several international journals and serves as a Doctoral Research Committee (DRC) Expert member at various Indian universities.
Affiliations and expertise
Associate Director Chandigarh University Mohali, PunjabPF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Cellular, Molecular and Genetic Medicine, VCU Institute of Molecular Medicine, VCU Massey Comprehensive Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, United StatesKT
Kenneth D. Tew
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
Affiliations and expertise
John C. West Chair in Cancer Research Hollings Cancer Ctr MUSC, Charleston SC.